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substitutions/site/month). Following seroconversion, there was
a striking increase in viral diversity. Most seroconverters had
viral variants that showed evidence of positive selection, which
was seen mainly postseroconversion. Conclusions: The high viral
diversity before a reduction in HBV DNA and before HBeAg sero-
conversion, could either be related to occurrence of stochastic
mutations that lead to a break in immune tolerance, or increased
immune reactivity that drives escape mutations. In a follow-up
study, we examined the long term evolution of HBV quasispecies
and whether the increase in viral diversity could be conﬁrmed.
Furthermore, we sought to determine if this increase in viral
diversity could result in creation of new CpG motifs, which could
stimulate Toll Receptor 9. TLR9 is one member of a family of
highly conserved molecular pattern recognition receptors-toll
like receptors, and is stimulated by unmethylated CpG dinu-
cleotides resulting in activation of the innate immune response
and consequently adaptive immune response. In this study, we
analyzed if there were any CpG sites in the HBV genome of
chronic hepatitis B patients and their relationship with HBeAg
seroconversion, using Eight HBeAg seroconverters followed up
6–10 years before seroconversion were included. Serum samples
of 5 to 9 time points before HBeAg seroconversion were used
in the study. Seven non-seroconverters with matching follow up
period and stored serum samples were involved as controls. An
identical methodology was used to evaluate 20 clones per serum
sample and analysed using the same methodology as previously.
HBV CpGs status was analyzed with the sequence alignments.
Results: The HBV quasispecies viral diversity gradually increased
from 1.4×10-3 to 1.2×10-2 within 9 years before HBeAg serocon-
version. Positive selection was detected in 5 of 8 seroconverters
in the study period. New CpG motifs also emerged before HBeAg
seroconversion. The increase of viral diversity was closely corre-
lated with the reduction of HBV DNA, HBeAg levels and increase
in frequency of precore stop codon mutation.
Conclusion: The gradual increase of HBV quasispecies over time
before HBeAg seroconversion could be related to accumulation
of stochastic mutations which result in occurrence of new CpG
motifs that activated the innate immune response and break the
immune tolerance leading to HBeAg seroconversion.
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Type I interferons have been used for almost 25 years to treat
hepatitis virus infections. While HCV infection can be cured in
50-80% of cases with IFN-based treatment regimens, the goal
of IFN-therapy of HBV infection is to induce an immune control
which is either associated with HBe seroconversion or even loss
of HBsAg. Obvious advantages of IFN therapies of chronic hep-
atitis B are ﬁnite treatment durations, the lack of resistance
development and higher off-treatment sustained response rates
as compared to HBV polymerase inhibitors. However, IFN alfa
may induce various side effects and the direct antiviral potency
is much weaker as compared to the recently approved nucleoside
and nucleotide analogues. The detailed mode of action of IFN
alfa in the treatment of chronic hepatitis B is poorly deﬁned.
Different effect of IFNa have been proposed: (i) IFNa directly
inhibits HBV replication which has been conﬁrmed by in vtro
models of HBV replication. (ii) IFNa may display various effects
on cells of the adaptive immune system including dendritic cells
and T cells. Some but not all studies suggest an impairment of
dendritic cells in chronic hepatitis B and IFNa may may enhance
antigen presentation, cytokine production and maturation of
dendritic cells. If IFNa treatment is associated with a reduction
of the in HBV infection increased frequency of regulatory T
cells (Tregs) has not been studied in detail yet. Impaired CD8+
T cell function is associated with a higher expression of PD-1
expression and blocking PD1-signalling can restore T cell activity.
It is generally believed that T cell function should be increased
by IFNa, however, IFNa has also antiproliferative capacities and
may therefore impair T cell proliferation. (iii) IFNa is believed
to enhance NK cell functions. We gained evidence that IFNa
increases the cytotoxic activity of NK cells via various mecha-
nisms including upregulation of certain molecules such as TRAIL.
(iv) The potential effects of IFNa on humoral immunity against
HBV are poorly deﬁned but several studies have shown already
that B cell priming and BCR crosslinking is improvied by IFNa.
(v) Toll-like receptor-2 expression is reduced in HBeAg-positive
hepatitis B. Preliminary data suggest that IFNa may increase
TLR-2 expression.
Overall, IFNa treatment is associated with a reduced virion
productivity. To what extent this due to direct intracellular
mechanisms or deletion of HBV-infected cells remains to be
determined. Future studies will have to deﬁne in more de-
tail which patients are good candidates of IFNa treatment and
which patients may beneﬁt from combination therapies with HBV
polymerase inhibitors.
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One interesting outcome of chronic hepatitis B virus infection
has been a more common development of end-stage liver dis-
eases in males than females. This gender disparity is more
striking in HBV-related liver cancer, in which male patients usu-
ally outnumber females to 5-7 folds. The hypothesis is proposed
either males more vulnerable to HBV-carcinogenesis or females
more protective against this process, or both. The hypothesis
has been supported by epidemiological investigations in which
higher androgen levels are correlated with more risk of HCC in
male carriers, and use of estrogen supplements reduces HCC
in female carriers. Now we present the results how human sex
hormones axis interacts with HBV. It was found that androgen
receptor could bind directly to HBV genome, via enhancer I, to
augment HBV transcription and replication. Besides, androgen
receptor can cooperate with HBV X protein to enhance down-
stream cancer-promoting pathway. In contrast, there are data
indicating female estrogen receptor able to down regulate HBV
gene transcription, maybe via a remodeling of viral genome. The
addition of estrogen to male HBV transgenic mice could reduce
HBV titers. These results may explain the mechanisms for a male
susceptibility to HBV-related end stage liver diseases and might
point out directions to anti-viral targets.
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Currently, Clostridium difﬁcile rivals methicillin-resistant
